Sunbelt Securities Inc. increased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 24.5% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 514 shares of the company’s stock after acquiring an additional 101 shares during the quarter. Sunbelt Securities Inc.’s holdings in Medpace were worth $208,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of the stock. LPL Financial LLC boosted its holdings in Medpace by 115.3% in the third quarter. LPL Financial LLC now owns 23,116 shares of the company’s stock worth $5,600,000 after acquiring an additional 12,380 shares in the last quarter. Stifel Financial Corp lifted its holdings in shares of Medpace by 58.6% in the 3rd quarter. Stifel Financial Corp now owns 24,254 shares of the company’s stock worth $5,873,000 after purchasing an additional 8,965 shares in the last quarter. Northern Trust Corp grew its position in Medpace by 4.0% in the 3rd quarter. Northern Trust Corp now owns 241,202 shares of the company’s stock valued at $58,402,000 after purchasing an additional 9,192 shares during the period. Trexquant Investment LP raised its holdings in Medpace by 283.1% during the third quarter. Trexquant Investment LP now owns 6,410 shares of the company’s stock worth $1,552,000 after buying an additional 4,737 shares during the last quarter. Finally, Treasurer of the State of North Carolina raised its holdings in Medpace by 0.5% during the third quarter. Treasurer of the State of North Carolina now owns 10,230 shares of the company’s stock worth $2,477,000 after buying an additional 50 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.
Medpace Stock Performance
Shares of NASDAQ:MEDP opened at $411.85 on Friday. The company has a market capitalization of $12.76 billion, a P/E ratio of 41.98, a price-to-earnings-growth ratio of 2.01 and a beta of 1.39. The company’s 50-day moving average is $397.13 and its 200 day moving average is $366.98. Medpace Holdings, Inc. has a fifty-two week low of $227.21 and a fifty-two week high of $437.39.
Insider Buying and Selling at Medpace
In other Medpace news, CEO August J. Troendle sold 4,782 shares of the business’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $400.58, for a total value of $1,915,573.56. Following the sale, the chief executive officer now directly owns 716,197 shares in the company, valued at $286,894,194.26. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, CEO August J. Troendle sold 4,782 shares of Medpace stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $400.58, for a total value of $1,915,573.56. Following the completion of the transaction, the chief executive officer now owns 716,197 shares in the company, valued at $286,894,194.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO August J. Troendle sold 3,987 shares of the company’s stock in a transaction that occurred on Friday, May 24th. The shares were sold at an average price of $395.22, for a total transaction of $1,575,742.14. Following the sale, the chief executive officer now owns 660,351 shares in the company, valued at $260,983,922.22. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 29,621 shares of company stock valued at $11,816,852. Company insiders own 20.30% of the company’s stock.
Wall Street Analysts Forecast Growth
MEDP has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft began coverage on shares of Medpace in a report on Monday, March 18th. They set a “hold” rating and a $395.00 price objective for the company. Guggenheim lifted their target price on Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Robert W. Baird increased their price target on Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and raised their price objective for the company from $340.00 to $450.00 in a research note on Tuesday, April 23rd. Finally, Mizuho assumed coverage on shares of Medpace in a research note on Tuesday, May 28th. They issued a “buy” rating and a $435.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, Medpace has a consensus rating of “Moderate Buy” and a consensus target price of $443.14.
Check Out Our Latest Research Report on MEDP
Medpace Company Profile
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
See Also
- Five stocks we like better than Medpace
- ETF Screener: Uses and Step-by-Step Guide
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- What Are Dividend Contenders? Investing in Dividend Contenders
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.